¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"exudative proliferative glomerulonephritis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • membranoproliferative glomerulonephritis
    ¸·Áõ½ÄÅ丮ÄáÆÏ¿°, ¸·Áõ½Ä»ç±¸Ã¼½Å¿°
  • membranous glomerulonephritis
    ¸·Å丮ÄáÆÏ¿°, ¸·»ç±¸Ã¼½Å¿°
  • mesangiocapillary glomerulonephritis
    Ç÷°ü»çÀÌÁú¸ð¼¼°üÅ丮ÄáÆÏ¿°, »ç±¸Ã¼Ç÷°ü°£Áú¸ð¼¼°ü»ç±¸Ã¼½Å¿°
  • poststreptococcal glomerulonephritis
    »ç½½¾Ë±Õ°¨¿°ÈÄÅ丮ÄáÆÏ¿°, ¿¬¼â±¸±Õ°¨¿°ÈĻ籸ü½Å¿°
  • rapidly progressive glomerulonephritis
    ±Þ¼ÓÁøÇàÅ丮ÄáÆÏ¿°, ±Þ¼ÓÁøÇà»ç±¸Ã¼½Å¿°
  • subacute diffuse glomerulonephritis
    ¾Æ±Þ¼º»êÀçÅ丮ÄáÆÏ¿°, ¾Æ±Þ¼º¹ü¹ß»ç±¸Ã¼½Å¿°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • glomerulonephritis
    Å丮ÄáÆÏ¿°, »ç±¸Ã¼½Å¿°
  • intercapillary glomerulonephritis
    ¸ð¼¼°üÅ丮ÄáÆÏ¿°, ¸ð¼¼°ü°£»ç±¸Ã¼½Å¿°
  • membranoproliferative glomerulonephritis
    ¸·Áõ½ÄÅ丮ÄáÆÏ¿°, ¸·Áõ½Ä»ç±¸Ã¼½Å¿°
  • membranous glomerulonephritis
    ¸·Å丮ÄáÆÏ¿°, ¸·»ç±¸Ã¼½Å¿°
  • mesangiocapillary glomerulonephritis
    »çÀÌÁú¸ð¼¼°üÅ丮ÄáÆÏ¿°, »ç±¸Ã¼°£Áú¸ð¼¼°ü»ç±¸Ã¼½Å¿°
  • poststreptococcal glomerulonephritis
    »ç½½¾Ë±Õ°¨¿°ÈÄÅ丮ÄáÆÏ¿°, ¿¬¼â±¸±Õ°¨¿°ÈĻ籸ü½Å¿°
  • rapidly progressive glomerulonephritis
    ±Þ¼ÓÁøÇàÅ丮ÄáÆÏ¿°, ±Þ¼ÓÁøÇà»ç±¸Ã¼½Å¿°
  • subacute diffuse glomerulonephritis
    ¾Æ±Þ¼º»êÀçÅ丮ÄáÆÏ¿°, ¾Æ±Þ¼º¹ü¹ß»ç±¸Ã¼½Å¿°
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • intercapillary glomerulonephritis
    ¸ð¼¼(Ç÷)°ü°£»ç±¸Ã¼½Å¿°.
  • membranous glomerulonephritis
    ¸·¼º»ç±¸ ü½Å¿°(¡­ÞêϹô÷ãìæú).
  • membranous glomerulonephritis
    ¸·¼º»ç±¸Ã¼½Å¿°(¡­Þêϳô÷ãìæú)
  • mesangiocapillary glomerulonephritis
    »ç±¸Ã¼°£Áú (¸Þ»êÁöÀ½)¸ð¼¼°ü¼º(Ù¾á¬Î·àõ) »ç±¸Ã¼½Å¿°
  • rapidly progressive (crescentic) glomerulonephritis
    ±Þ¼ÓÁøÇ༺»ç±¸Ã¼½Å¿°(ÐááÜòäú¼àõÞêϹô÷ãìæú)
  • rapidly progressive glomerulonephritis
    ±Þ¼ÓÁøÇ༺ »ç±¸Ã¼½Å¿°.
  • subacute diffuse glomerulonephritis
    ¾Æ±Þ¼º ¹ü¹ß¼º »ç±¸Ã¼½Å¿°(¡­ÛñÛ¡àõÞêϹ ô÷ãìæú).
  • subacute diffuse glomerulonephritis
    ¾Æ±Þ¼º ¹ü¹ß¼º »ç±¸Ã¼½Å¿°(¡­ÛñÛ¡àõÞêϹ ô÷ãìæú)
  • subacute glomerulonephritis
    ¾Æ±Þ¼º »ç±¸Ã¼½Å¿°(¡­ÞêϹô÷ãìæú).
  • subacute glomerulonephritis
    ¾Æ±Þ¼º »ç±¸Ã¼½Å¿°(¡­ÞêϹô÷ãìæú)
  • dominant exudative vitreoretinopathy
    ¿ì¼º»ïÃâÀ¯¸®Ã¼¸Á¸·º¯Áõ
  • external exudative retinopathy
    ¿Ü»ïÃâ¸Á¸·º´Áõ
  • exudative
    »ïÃ⼺(ß¶õóàõ)ÀÇ.
  • exudative albuminuria
    »ïÃ⼺ ´Ü¹é´¢.
  • exudative arthritis
    »ïÃ⼺ °üÀý¿°.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
EVXX exudative vitreoretinopathy, X-linked
FEV familial exudative vitreoretinopathy; forced expiratory volume
FEVR familial exudative vitreoretinopathy
IPSID Immuno-Proliferative Small Intestine Disease
MPGN Mesangial(Membrano-) Proliferative Glomerulo-Nephritis
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PKD Proliferative Kidney Disease
PVR Proliferative Vitreoretinopathy
PA Proliferative activity
PCNA Proliferative cell nuclear antigen
PDR Proliferative diabetic retinopathy
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
acute post-streptococcal glomerulonephritis <nephrology> A disease of the kidneys that results in inflammation of the glomerulus (the portion of the kidney that filters the blood).
Conditions which may cause glomerulonephritis include post-streptococcal disease (strep throat), lupus, syphilis, bacterial endocarditis, membranoproliferative glomerulonephritis, sepsis, vasculitis, Goodpasture's syndrome, typhoid fever, Henoch-Schonlein purpura, hepatitis or a viral infection (for example mumps, measles, mononucleosis).
(27 Sep 1997)
anti-basement membrane glomerulonephritis Glomerulonephritis resulting from anti-basement membrane antibodies, characterised by smooth linear deposits of IgG and C3 along glomerular capillary walls; includes rapidly progressive glomerulonephritis and glomerulonephritis in Goodpasture's syndrome.
(05 Mar 2000)
Berger's focal glomerulonephritis Glomerulonephritis affecting a small proportion of renal glomeruli which commonly presents with haematuria and may be associated with acute upper respiratory infection in young males, not usually due to streptococci; associated with IgA deposits in the glomerular mesangium and may also be associated with systemic disease, as in Henoch-Schonlein purpura.
Synonym: Berger's disease, Berger's focal glomerulonephritis, focal nephritis, IgA nephropathy.
(05 Mar 2000)
rapidly progressive glomerulonephritis <nephrology> A relatively uncommon (affecting 1 out of 10,000 people) form of acute glomerulonephritis that results in damage within the glomerulus of the kidney. There is rapid loss of kidney function with the formation of crescents on microscopic analysis (kidney biopsy). This disorder may result in acute glomerulonephritis or nephrotic syndrome, but ultimately results in renal failure and end-stage renal disease.
Symptoms include smoky coloured urine (pyuria), decreased urine output, swelling and hypertension. Any conditions which can cause a vasculitis increase the risk of this disorder. Some examples include lupus, Goodpasture's syndrome, Henoch-Schonlein purpura, IgA nephropathy, membranoproliferative glomerulonephritis, anti-glomerular basement membrane antibody disease, history for malignant tumours and exposure to hydrocarbon solvents.
(27 Sep 1997)
glomerulonephritis <nephrology> A variety of nephritis characterised by inflammation of the capillary loops in the glomeruli of the kidney. It occurs in acute, subacute and chronic forms and may be secondary to haemolytic streptococcal infection. Evidence also supports possible immune or autoimmune mechanisms.
(18 Nov 1997)
glomerulonephritis, IgA Chronic form of glomerulonephritis characterised by recurring haematuria with only slight proteinuria and by deposits of IgA immunoglobulin in the mesangial areas of the renal glomeruli. It usually occurs in young males.
(12 Dec 1998)
glomerulonephritis, membranoproliferative Chronic glomerulonephritis characterised histologically by proliferation of mesangial cells, increase in the mesangial matrix, and a thickening of the glomerular capillary walls. The wall thickening is sometimes said to be a result of the interposition of mesangial cytoplasm or matrix between the basement membrane and the endothelium of the capillary wall. It is often divided into types I and II, and sometimes III. Pathogenesis is not well understood, but some types are thought to involve the immune system, with the complement system, in particular, being implicated.
(12 Dec 1998)
glomerulonephritis, membranous A disease of the glomerulus manifested clinically by proteinuria, and sometimes by other features of the nephrotic syndrome. It is histologically characterised by deposits in the glomerular capillary wall between the epithelial cell and the basement membrane and a thickening of the membrane. Also characteristic are outward projections of the membrane between the epithelial deposits in the form of "spikes". There is some agreement that the deposits are antigen-antibody complexes.
(12 Dec 1998)
membranoproliferative glomerulonephritis <pathology> A kidney disorder which results in kidney dysfunction. Inflammation of the glomeruli result from an abnormal immune response and the deposition of antibodies within the kidney (glomerulus) ultrastructure.
Membranoproliferative glomerulonephritis has been divided into two different types in the basis of where the antibodies are deposited in the glomerulus. MPGN type I, the more common type, deposits antibodies in the subendothelial layer of the basement membrane, whereas type II deposits antibodies in the bottom layer of the basement membrane.
Symptoms include cloudy urine (pyuria), decreased urine output, swelling and hypertension. This disorder often results in end-stage renal disease.
Acronym: MPGN
(26 Mar 1998)
membranous glomerulonephritis <pathology> A kidney disease that occurs due to inflammation of the kidney glomerulus and its basement membrane.
The exact cause is unknown but it appears to be related to the deposition of immune complexes in the basement membrane leading to thickening of the capillary walls. This disorder is a common cause of nephrotic syndrome an is usually how the disease manifests.
Risk factors include primary renal disease, malaria, hepatitis B, lupus, syphilis, cancers and non-Hodgkin's lymphomas. Risks also include exposure to some medications such as gold compounds and penicillamine. Mercury, trimethadione and some skin-lightening creams have also been implicated.
Treatment includes systemic corticosteroids and immunosuppressive agents.
(26 Mar 1998)
mesangiocapillary glomerulonephritis <nephrology, pathology> A kidney disorder which results in kidney dysfunction. Inflammation of the glomeruli result from an abnormal immune response and the deposition of antibodies within the kidney (glomerulus) ultrastructure.
Membranoproliferative glomerulonephritis has been divided into two different types in the basis of where the antibodies are deposited in the glomerulus. MPGN type I, the more common type, deposits antibodies in the subendothelial layer of the basement membrane, whereas type II deposits antibodies in the bottom layer of the basement membrane.
Symptoms include cloudy urine (pyuria), decreased urine output, swelling and hypertension. This disorder often results in end-stage renal disease.
(27 Sep 1997)
chronic glomerulonephritis Glomerulonephritis that presents with persisting proteinuria, chronic renal failure, and hypertension, of insidious onset or as a late sequel of acute glomerulonephritis; the kidneys are symmetrically contracted and granular, with scarring and loss of glomeruli and the presence of tubular atrophy and interstitial fibrosis.
Synonym: chronic nephritis.
(05 Mar 2000)
crescentic glomerulonephritis <nephrology, pathology> A relatively uncommon (affecting 1 out of 10,000 people) form of acute glomerulonephritis that results in damage within the glomerulus of the kidney. There is rapid loss of kidney function with the formation of crescents on microscopic analysis (kidney biopsy). This disorder may result in acute glomerulonephritis or nephrotic syndrome, but ultimately results in renal failure and end-stage renal disease.
Symptoms include smoky coloured urine (pyuria), decreased urine output, swelling and hypertension. Any conditions which can cause a vasculitis increase the risk of this disorder. Some examples include lupus, Goodpasture's syndrome, Henoch-Schonlein purpura, IgA nephropathy, membranoproliferative glomerulonephritis, anti-glomerular basement membrane antibody disease, history for malignant tumours and exposure to hydrocarbon solvents.
(27 Sep 1997)
segmental glomerulonephritis Glomerulonephritis affecting only part of a glomerulus or glomeruli.
Synonym: local glomerulonephritis.
(05 Mar 2000)
hypocomplementemic glomerulonephritis <pathology> A kidney disorder which results in kidney dysfunction. Inflammation of the glomeruli result from an abnormal immune response and the deposition of antibodies within the kidney (glomerulus) ultrastructure.
Membranoproliferative glomerulonephritis has been divided into two different types in the basis of where the antibodies are deposited in the glomerulus. MPGN type I, the more common type, deposits antibodies in the subendothelial layer of the basement membrane, whereas type II deposits antibodies in the bottom layer of the basement membrane.
Symptoms include cloudy urine (pyuria), decreased urine output, swelling and hypertension. This disorder often results in end-stage renal disease.
Acronym: MPGN
(26 Mar 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á